RSRebecca L. Smith

Rebecca L. Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rebecca L. Smith has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Antony B. Friedman

    Department of Gastroenterology, Alfred Hospital and Monash University

    3 shared publications
  • Kirstin M. Taylor

    Department of Gastroenterology, Alfred Hospital and Monash University

    3 shared publications
  • Peter R. Gibson

    Department of Gastroenterology, Alfred Hospital and Monash University

    3 shared publications
  • Antony B Friedman

    Department of Gastroenterology Alfred Hospital Melbourne Victoria Australia

    2 shared publications
  • Danny Con

    Department of Gastroenterology, Eastern Health, Melbourne, Australia

    2 shared publications
  • David J. Gibson

    Department of Gastroenterology, Alfred Hospital and Monash University

    2 shared publications

Latest Publications

  • Open Access

    Effects of Stress, Vagal Nerve Stimulation and Disease Activity on Circulating Cytokines, Quantified by an Ultrasensitive Technique, in Ulcerative Colitis: A Pilot Study

    by Tamara Mogilevski, Melinda Y. Hardy, Kazuya Takahashi, Rebecca Smith, Anke L. Nguyen, Adam Farmer, James O. Lindsay, Jason A. Tye‐Din, Qasim Aziz, Peter R. Gibson

    Aims: The utility of circulating cytokine concentrations in ulcerative colitis is limited due to poor assay sensitivity. We aimed to examine the relationship of circulating cytokine concentrations, when measured by ultrasensitive detection, to disease activity, response to induction therapy, and physiological stimuli associated with mucosal injurious events.Methods: Plasma was obtained from adult patients with ulcerative colitis in whom disease activity was assessed; before/after induction therapy; and before/after acute psychological stress and cervical transcutaneous vagal nerve/sham stimulation. Cytokines were measured using an ultrasensitive electrochemiluminescence‐based multiplex assay. For stress/vagal‐stimulation studies, epithelial injury was quantified by plasma concentrations of intestinal‐type fatty acid‐binding protein.Results: In 12 patients in remission, 15 with mild‐moderately active disease and 6 with severe colitis, concentrations of interleukin‐17, IL10, interferon‐γ, interleukin‐8 and interleukin‐6, but not tumor necrosis factor‐α or interleukin‐12p70, significantly reflected disease activity. In five patients in whom clinical remission was achieved with induction therapy, only interleukin‐12p70 changed with a median increase of 65 (IQR 42–303)% (p = 0.006), with no consistent changes in the 10 not in remission. Vagal nerve stimulation had no effect on cytokine concentrations, but, following stress, interleukin‐12p70 increased by 37 (13–60)% compared with a reduction of 29 (3–55)% following sham stimulation (p = 0.012), an effect that mirrored that of epithelial injury.Conclusion: Multiple cytokines were detected at sub‐pg/mL levels and many showed relationships to disease activity in patients with ulcerative colitis. Effects exerted by interventions associated with epithelial injury were consistently detected by changes in interleukin‐12p70 concentrations, but not other cytokines.Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12621000168853 and ANZCTR 12620000569909 [Ultrasound studies]; ClinicalTrials.gov identifier: NCT03908073


  • Open Access

    Clinical Trial: The Effects of Emulsifiers in the Food Supply on Disease Activity in Crohn's Disease: An Exploratory Double‐Blinded Randomised Feeding Trial

    by Jessica A. Fitzpatrick, Peter R. Gibson, Kirstin M. Taylor, Ellen J. Anderson, Antony B. Friedman, Zaid S. Ardalan, Rebecca L. Smith, Emma P. Halmos

    Background: Advice to avoid dietary emulsifiers in Crohn's disease (CD) is based on preclinical data.Aims: To examine the effect of diets high (HED) and low (LED) in emulsifiers in the food supply on disease activity in CD.Methods: In a double‐blinded, randomised feeding study, we randomised adults with symptomatic, sonographically active CD with ileal involvement on ≥ 2 months' stable medical therapy to 4 weeks of a HED or LED modelled on Australian healthy eating guidelines. We measured the Harvey‐Bradshaw Index (HBI), sonographic indices (IBUS‐SAS, bowel wall thickness), quality of life (QOL) and fatigue at baseline and study completion.Results: We randomised 24 patients, mean age 37 (95% CI 32, 41) years, 12 male, HBI 6 (6, 8), bowel wall thickness 6.0 (5.5–6.6) mm. Adherence was > 95%. Clinical remission (HBI < 5) occurred in 9/12 on HED and 7/12 on LED; 2 and 3, respectively, withdrew early with increasing gastrointestinal symptoms. IBUS‐SAS fell from 51 (35, 68) to 33 (15, 51) on HED (p = 0.014) and from 57 (38, 76) to 44 (29, 59) on LED (p = 0.01). Bowel wall thickness reduced by 34% on HED and 15% on LED in those who completed the study. QOL and fatigue improved on both diets (p ≤ 0.05). There were no statistically significant differences in outcomes between diets.Conclusions: In the context of a healthy diet, the emulsifier content had no influence over disease activity over 4 weeks in patients with CD. Recommendations to avoid emulsifiers in patients with active CD are not supported.Australian New Zealand Clinical Trials Registry (ACTRN12619001099112).


  • Open Access

    Nonspecific ileitis: Impact of histopathology and gastrointestinal ultrasound in achieving the diagnosis of Crohn's disease

    by Rebecca L Smith, Kirstin M Taylor, Antony B Friedman, Ammar Majeed, Natalie Perera, Peter R Gibson

    Background and Aim: Nonspecific ileitis is inflammation of the ileum without specific diagnostic features. A minority may go on to develop Crohn's disease, but optimal pathways of further investigation have not been established. This study aimed to identify a cohort of patients with nonspecific ileitis and to determine the value of ileal histology and gastrointestinal ultrasound in identifying/excluding Crohn's disease.Patients and Methods: In a retrospective analysis, all patients having nonspecific ileitis at colonoscopy from January 2010 to August 2021 were identified. Clinical associations with those subsequently diagnosed with Crohn's disease were examined with specific reference to ileal histology and gastrointestinal ultrasound.Results: Of 29 638 procedures, 147 patients (0.5%) had nonspecific ileitis. Crohn's disease was subsequently diagnosed in 8 patients (5.4%) at a median of 148 (range 27–603) days after colonoscopy. The presence of chronic inflammation on ileal biopsies was more common in those subsequently diagnosed with Crohn's disease (63% vs 20%; P = 0.0145). On gastrointestinal ultrasound, none of the 26 patients with normal bowel wall thickness (<3 mm) were subsequently diagnosed with Crohn's disease, and repeat ultrasound in 15 patients 1 year later showed no change. Of the nine patients with abnormal sonographic findings, three were diagnostic for Crohn's disease. Repeat ultrasound revealed Crohn's disease in two, while four had resolution of the abnormal findings.Conclusion: Although ileal histology was of limited value in identifying patients with nonspecific ileitis who were subsequently diagnosed with Crohn's disease, gastrointestinal ultrasound was highly informative. Prospective studies are needed to confirm the value of gastrointestinal ultrasound as a diagnostic and monitoring tool in this setting.


  • Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease

    by Rebecca L. Smith, Kirstin M. Taylor, Antony B. Friedman, David J. Gibson, Danny Con, Peter R. Gibson

    Objective: Gastrointestinal ultrasound (GIUS) accurately assesses inflammation and is responsive to changes in inflammatory bowel disease. This study aimed to determine the prognostic utility of sonographic response in the first 14 weeks of a newly-instituted therapy with therapeutic response at 46 weeks and to compare its performance with standard clinical assessment tools. Methods: Patients with sonographic evidence of inflammation were assessed by GIUS, clinical activity, serum C-reactive protein and faecal calprotectin again 2, 6 and 14 weeks after commencing a new biologic or thiopurine. Treatment failure was defined as undergoing surgery, hospitalisation, escalation of dosage or introduction of new medication over 46-weeks’ follow-up. Sonographic response was defined as a decrease in bowel wall thickness and improved vascularity. Results: In 31 patients (median age 49 years, 74% Crohn’s disease), sonographic response at 14 weeks [OR 19.3, 95% confidence interval (CI), 3.23–101.10; P = 0.0054] and faecal calprotectin (P = 0.018), but no clinical disease activity or C-reactive protein, were predictive of subsequent treatment response. Sonographic response alone was predictive at week 6 (P = 0.016), but not week 2. 16% reduction in bowel wall thickness at 6 weeks (area-under-the-receiver-operator-curve=0.86; P = 0.002; sensitivity 72%, specificity 90%), with similar performance for 10% at 14 weeks, was associated with treatment response. Conclusion: Sonographic response as early as 6 weeks after initiation of a new therapy may accurately predict treatment outcomes over 46 weeks and is superior to other markers used to monitor disease activity.


  • Interrater reliability of the assessment of disease activity by gastrointestinal ultrasound in a prospective cohort of patients with inflammatory bowel disease

    by Rebecca L. Smith, Kirstin M. Taylor, Antony B. Friedman, Heidi Y. Su, Danny Con, Peter R. Gibson

    Objective: Gastrointestinal ultrasound is a radiological investigation for monitoring patients with inflammatory bowel disease. However, the reliability of the findings depends on the reproducibility of results between different operators. Thus, the study aim was to assess the interrater reliability of gastrointestinal ultrasound in individuals with inflammatory bowel disease between gastroenterologists with varying GIUS experience. Methods: Patients were prospectively recruited at the commencement of a new medical therapy for a baseline assessment, with a second assessment at the end of treatment induction (3 months). Consecutive, blinded ultrasounds were performed by two operators for every test. Gastrointestinal ultrasound examination included assessment of bowel wall thickness, vascularity, wall stratification assessment, mesenteric hyperechogenicity and lymphadenopathy. Results: Forty-nine patients were recruited (Crohn’s n = 27, ulcerative colitis n = 22) with 35 returning for a repeat assessment at 3 months. At baseline, the intraclass coefficient for bowel wall thickness was near perfect (0.882). By bowel segment, the closest correlation was in the terminal ileum and differences in bowel wall thickness were similar by disease subtype. All other ultrasound indices of disease activity demonstrated substantial to near-perfect agreement with Gwet’s agreement coefficient: vascularity (0.681), wall stratification (0.685), mesenteric hyperechogenicity (0.841) and lymphadenopathy (0.633). Similar findings were seen at 3 months. Conclusion: There is substantial agreement between operators of varying experience in gastrointestinal ultrasound findings in patients with Crohn’s disease or ulcerative colitis and this is repeatedly demonstrated over time. Thus, a well-trained operator should be sufficient to assess disease activity in patients with inflammatory bowel disease.


  • Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis

    by Rebecca L Smith, Kirstin M Taylor, Antony B Friedman, Robert N Gibson, Peter R Gibson

    Background and Aims: Gastrointestinal ultrasound is useful in the assessment of patients with Crohn’s disease, but its application in ulcerative colitis [UC] is less well established. Here we systematically review the role of gastrointestinal ultrasound in patients with UC. Methods: Searches of the PUBMED and EMBASE databases were performed with the following search strategy: [ultrasound OR sonography] AND [intestinal OR bowel] AND [ulcerative colitis OR inflammatory bowel disease]. The final search was performed in August 2019. Results: Of 6769 studies identified in the search with a further two studies found from other sources, 50 studies met the inclusion criteria. Increased bowel wall thickness and detection of increased blood flow by colour Doppler were the most often applied criteria for defining disease activity and distribution. When compared with other reference investigations, gastrointestinal ultrasound accurately determined disease extent, severity and response to medical therapy. While further information can be obtained from haemodynamic measurements of the abdominal vessels and contrast-enhanced ultrasound, their clinical value was uncertain. Likewise, hydrocolonic sonography has few advantages over standard gastrointestinal ultrasound examination. Of several scoring systems proposed, there is disparity between the measures and a general lack of validation. There has been limited application of gastrointestinal ultrasound in acute severe ulcerative colitis with toxic megacolon, and, while performing well in children, normal limits differ from those in adults. Conclusion: Current evidence indicates that gastrointestinal ultrasound has utility in the non-invasive assessment of patients with UC. Continued advances in technology with better image resolution, validation of scoring systems and application at the point of care by gastroenterologists are likely to contribute to increased use of gastrointestinal ultrasound in routine clinical practice.